Novartis to Acquire Avidity Biosciences for $12 Billion
Novartis has announced an agreement to acquire Avidity Biosciences, a biopharmaceutical company focused on RNA delivery to muscle.
The acquisition will bring Avidity's late-stage neuroscience programs to Novartis, providing access to a differentiated RNA-targeting delivery platform.
- Acquisition price: $12 billion
- Avidity's early-stage precision cardiology programs will be separated
- Novartis will gain potential first-in-class therapeutic candidates for muscle-damaging conditions
No direct quote available in the text.
Author's summary: Novartis acquires Avidity Biosciences for $12 billion.
More News
- D&H Distributing’s Advanced Solutions Plus Unit To Focus On The Enterprise, ‘A Pivotal Evolution’ For Its Business
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- MMJ BioPharma Cultivation: EXPOSÉ: DEA's Marijuana Licensing Scheme Exposed - MMJ BioPharma's Case Reveals DEA Contradiction Blocking FDA Approved Cannabis Medicine
- Racial Disparities Persist in Victim Compensation for Homicide Survivors
- Managing Benign Prostatic Hyperplasia: Your BPH Treatment Options
- ACCC sues Microsoft over alleged misleading subscription practices in Australia
- Australia is Suing Microsoft Over Misleading Microsoft 365 Price Hikes
- CRC Screening Improvements Decrease Mortality, but Disparities Persist
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow